News & Updates
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.
Hyfe’s AI-powered cough monitoring is now available on Actigraph’s FDA-cleared LEAP wearable, enabling continuous, privacy-preserving cough tracking alongside key health biomarkers
Clinical Trial Results Demonstrate Alkaline Magnesium-Based Salt Aerosol Reduced Cough Frequency by up to 35% in Refractory Chronic Cough Patients with Cough Counts Measured Continuously by AI-Powered tech
Hyfe's cough tracker was used in study by University of Navarra, revealing significant variability in cough patterns. This breakthrough highlights potential for continuous, objective chronic cough monitoring.
CoughPro app introduces the world’s first digital Cough Management feature, offering AI-driven solutions for millions suffering from chronic cough.
Research demonstrates the accuracy of Hyfe’s automated cough monitoring process and is the first to observe differences in type and length of cough between men and women.
AI company transitions app to subscription model and adds exclusive new features for users in the UK, Canada, Europe and global users outside the U.S.
Hyfe's technology integrated into ActiGraph’s new FDA-cleared LEAP wearable device that will advance the use of remote patient monitoring in chronic cough clinical research.
Studies show remote patient monitoring technology better predicts cough exacerbations to ultimately improve quality of life and reduce healthcare costs for patients with chronic cough.
Hyfe is expanding into chronic cough treatment with the world's first digital therapeutic for cough, using a proprietary model that combines real time cough frequency with cough suppression therapy.
150 winners selected out of 13,000 private companies; Hyfe recognized for contributions in screening, monitoring and diagnostics technologies
Hyfe has entered into an agreement with Merck, to integrate its artificial intelligence-powered (AI) cough tracker technology into Merck’s consumer disease educational efforts.
Leader in acoustic epidemiology empowers health care providers, researchers, pharmaceutical companies, and patients with cough detection and classification platform
Scientists use Hyfe to confirm that continuous cough monitoring for Long COVID was more sensitive in evaluating cough variability and response to treatment compared to patient reported outcomes.
Dr. Peter Small, Hyfe Chief Medical Officer has delivered deliver an intervention to the G20 Meeting in Yogyakarta, Indonesia, on the role of digital innovation in addressing public health crises.
With apps and artificial intelligence, researchers want to use the cough to better diagnose asthma, Covid-19 and other respiratory illnesses
Accomplished physician, scientist, and product developer to lead Hyfe's efforts as it seeks to transform patient care through cough monitoring and diagnosis.
Wilmington, Del., Dec. 7, 2023 -- Hyfe, Inc., the global leader in AI-powered cough detection, tracking and classification, announces today the next generation of its CoughPro app, a platform available in the UK, Canada, and Europe that allows users to track and manage their cough in real-time. The app is moving to a subscription model and rolling out new features, including novel cough measurement tools, more personalized insights and self-care tips, and the first network connecting chronic coughers to their peers and healthcare professionals.
CoughPro’s new premium features include:
We built CoughPro with a mission to provide the world’s only reliable, user-friendly product for helping individuals with chronic cough better understand their cough and facilitate better communication with their providers. Since 2020, we've been thrilled to see how our apps have made a difference in so many people’s lives, and are more excited than ever to continue driving innovation in this space and bringing coughers the most reliable, science-based technology possible.
Dr. Joe Brew
Co-founder and CEO of Hyfe
Released in 2022, CoughPro is powered by the world’s leading AI cough detection models that identify and monitor cough continuously. As the leader in cough monitoring with over 18 billion data points processed coming from 160+ countries, Hyfe’s technology can track and detect cough in real-world conditions with 90% accuracy on any mic-enabled device, while preserving privacy by processing all sounds directly on the user’s device.
Building and maintaining the world’s best performing AI models requires significant resources, and the subscription model is a necessary step to maintain the high-quality service and innovation without ever compromising privacy through ads or selling data. We are so excited for this next chapter of CoughPro and look forward to working alongside our partners and users to offer critical support for their cough.
Reid Moorsmith
Chief Experience Officer
Starting today, CoughPro will offer two subscription options, a monthly subscription ($5.99 per month) and an annual subscription ($34.99 per year). To download the CoughPro app on Android or iOS and learn more about the updated features and pricing, click here.
For more information about Hyfe AI, visit Hyfe.ai.
Disclaimer:
The accuracy of the data collected and presented by Hyfe has not yet been evaluated by the FDA or other regulatory authorities and is not intended to be used in any medical decision making capacity, including presenting Hyfe-gathered cough information to a healthcare professional for management of a patient's cough-related symptoms or conditions.
About Hyfe
Hyfe, Inc. is the global leader in AI-powered cough detection and classification that provides insight into cough patterns and correlations that can greatly improve treatment and prevention. With more than 700 million samples, Hyfe maintains the largest cough dataset in the world enabling the building of powerful models to track, manage and diagnose respiratory illnesses.
Hyfe provides platforms and data for pharmaceutical companies, medical researchers, government agencies, health care providers and patients and has partnerships with leading academic institutions including Johns Hopkins University and the University of California at San Francisco. The company was founded in 2020 and is headquartered in Wilmington, Delaware. More information is available at hyfe.com on social media @hyfeapp and LinkedIn at /hyfe.
###
Media Contact:
press@hyfe.ai
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.